by Peter Ciszewski | Jul 5, 2018
Alnylam Pharmaceuticals announced the publication of the pivotal study results from the APOLLO Phase 3 trial of patisiran in The New England Journal of Medicine (NEJM). The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of...
by Peter Ciszewski | Jul 3, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. James McArthur, PhD, Founder of Imara and President, R&D of Imara discusses the development of IMR-687 for the treatment or rare hemoglobinopathies. Dr....
by Peter Ciszewski | Jul 3, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Manu Nair, Vice President of Technology Ventures at Oklahoma Medical Research Foundation (OMRF) discusses his group’s focus on building partnerships with...
by Peter Ciszewski | Jul 3, 2018
The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Cyprium Therapeutics’ Copper Histidinate, (CUTX-101), for patients diagnosed with classic Menkes disease who have not demonstrated significant clinical progression. Stephen G. Kaler,...
by Peter Ciszewski | Jul 1, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Barry Greene, President of Alnylam, discusses his company and it’s pending approval of Patisiran, an investigational RNAi therapeutic targeting...
